Certolizumab pegol for induction of remission in Crohn's disease
Clicks: 285
ID: 111310
2019
Moderate certainty evidence suggests that CZP is effective for induction of clinical remission and clinical response in participants with active CD patients. It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small d …
| Reference Key |
h2019thecertolizumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yamazaki H;So R;Matsuoka K;Kobayashi T;Shinzaki S;Matsuura M;Okabayashi S;Kataoka Y;Tsujimoto Y;Furukawa TA;Watanabe N;; |
| Journal | The Cochrane database of systematic reviews |
| Year | 2019 |
| DOI | DOI not found |
| URL | |
| Keywords |
systematic review
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
Remission Induction
randomized controlled trials as topic
Antibodies
Monoclonal
Humanized / therapeutic use*
pmid:31476018
pmc6718195
doi:10.1002/14651858.cd012893.pub2
hajime yamazaki
ryuhei so
norio watanabe
certolizumab pegol / therapeutic use*
crohn disease / drug therapy*
immunologic factors / therapeutic use
induction chemotherapy
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.